About: COVID-19 EXTRAPULMONARY ILLNESS – SPECIAL GASTROINTESTINAL AND HEPATIC CONSIDERATIONS

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 EXTRAPULMONARY ILLNESS – SPECIAL GASTROINTESTINAL AND HEPATIC CONSIDERATIONS Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 EXTRAPULMONARY ILLNESS – SPECIAL GASTROINTESTINAL AND HEPATIC CONSIDERATIONS
Source	Elsevier; Medline; PMC
abstract	Coronaviruses have caused three global outbreaks in the last 20 years, which include Severe Acute Respiratory Syndrome (SARS) caused by SARS-CoV (SARS-CoV-1), Middle East Respiratory Syndrome (MERS) by MERS-CoV and Coronavirus Disease-2019 (COVID-19) due to SARS-CoV-2. These outbreaks share many similarities, including clinical presentation, transmission, and management. Although respiratory manifestations are responsible for most of the morbidity and mortality in these conditions, extra-pulmonary manifestations such as gastrointestinal symptoms are also increasingly recognized as important symptoms. Important gastrointestinal symptoms include nausea, vomiting, anorexia, diarrhea, and abdominal pain. Hepatic manifestations such as abnormal aminotransferases are also noted in these patients. Early identification of GI symptoms is crucial as some patients can present only with GI manifestations in the absence of pulmonary symptoms. Furthermore, patients with diarrhea have tested positive for viral RNA in the stool. This has been reported even after the resolution of respiratory symptoms and can extend up to many days from the onset of symptoms. Because of this phenomenon, there is a theoretical risk of fecal-oral transmission and the potential spread of the disease. Though GI symptoms are frequently observed, understanding the pathogenesis of these symptoms is crucial, as it can not only of public health importance but could also identify infected patients early in the spread. Understanding the different GI and hepatic manifestations with underlying mechanisms of symptoms can assist in the therapeutic management of these patients. In this article, we summarize various GI and hepatic manifestations with their prevalence, underlying pathophysiology with emphasis on stool positivity.
has issue date	2020-07-28(xsd:dateTime)
bibo:doi	10.1016/j.disamonth.2020.101064
bibo:pmid	32807535
has license	no-cc
sha1sum (hex)	da7b751f51bc858502ced031be77641c6a6f2fbd
schema:url	https://doi.org/10.1016/j.disamonth.2020.101064
resource representing a document's title	COVID-19 EXTRAPULMONARY ILLNESS – SPECIAL GASTROINTESTINAL AND HEPATIC CONSIDERATIONS
has PubMed Central identifier	PMC7386425
has PubMed identifier	32807535
schema:publication	Dis Mon
resource representing a document's body	covid:da7b751f51bc858502ced031be77641c6a6f2fbd#body_text
is schema:about of	named entity 'anorexia' named entity 'non-specific' named entity 'MERS' named entity '95% CI' named entity 'COVID-19' named entity 'diarrhea' named entity 'leukopenia' named entity 'antibiotics' named entity 'directly related' named entity 'route of transmission' named entity 'viral RNA' named entity 'multiorgan failure' named entity 'organ systems' named entity 'gut flora' named entity '95% CI' named entity 'SARS' named entity 'dysgeusia' named entity 'central nervous' named entity 'Arabian Peninsula' named entity '95% CI' named entity 'mucous membranes' named entity 'cytopathic effects' named entity 'esophagus' named entity 'hepatic' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'anorexia' named entity 'watery diarrhea' named entity 'COVID-19' named entity 'anorexia' named entity 'diarrhea' named entity 'fever' named entity 'Immunosuppressive medications' named entity 'antiviral' named entity 'gut flora' named entity 'distal' named entity 'diarrhea' named entity 'cytokine storm syndrome' named entity 'epidemic' named entity 'abdominal pain' named entity 'IBD' named entity 'vomiting' named entity 'vomiting' named entity 'virus' named entity 'Interleukin-2' named entity 'diarrhea' named entity 'water treatment' named entity 'systematic review' named entity 'IL-17' named entity 'GI bleeding' named entity 'Diarrhea' named entity 'risk of transmission' named entity 'nausea' named entity 'antiviral medications' named entity 'loss of appetite' named entity 'nausea' named entity 'gastric mucosa' named entity 'diarrhea' named entity 'RNA' named entity 'T-cell' named entity 'duodenum' named entity '21%' named entity 'nausea and vomiting' named entity 'outpatient' named entity 'GM-CSF' named entity 'lipase' named entity 'nausea' named entity 'health concern' named entity 'asymptomatic' named entity 'diarrhea' named entity 'secondary bacterial infections' named entity 'hepatocytes' named entity 'human-to-human' named entity 'diarrhea' named entity 'enteral feeding' named entity 'hypothalamus' named entity 'epidemiological study' named entity 'therapeutic drug targets' named entity 'portal vein' named entity '95% CI' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software